ScreenerHero
VIVEVivesto ABPartial data
STO · SE · Healthcare · Drug Manufacturers - Specialty & Generic · vivesto.com
8.780SEK-2.34%Mkt Cap: 9.30M $P/E: —

Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for th…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap9.30M $
Enterprise Value7.26M $
Revenue (TTM)765 $
Gross Profit765 $
Net Income (TTM)-3.26M $
Revenue/Share0.0001 USD
Last Price8.780 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees4
CountrySE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINSE0028925701
Valuation
P/E (Trailing)—
P/E (Forward)-89.50
PEG—
EV/EBITDA-2.46
EV/Revenue9483.58
P/S12386.09
P/B38.58
EPS (TTM)-4.48
EPS (Forward)-0.10
52W Range
7.0009% of range27.76
52W High27.76 SEK
52W Low7.000 SEK
Profitability
Gross Margin100.00%
Oper. Margin-107825.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-27.36%
ROA-22.87%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.25M $
CapEx (TTM)942.27K $
FCF Margin-209673.44%
FCF Yield-17.26%
Net Debt-2.25M $
Net Debt/EBITDA0.76
Balance Sheet
Debt/Equity0.10
Current Ratio2.48
Quick Ratio2.39
Book Value/Sh0.2320 SEK
Cash/Share2.132 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:100
Split DateMay 20, 2026
Analyst Consensus
Rating0.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)24.00 SEK
Upside (mean)+173.3%
Target Range24.00 SEK – 24.00 SEK
# Analysts1
Ownership
Shares Out.11.07M
Float6.22M
Insiders47.33%
Institutions10.20%
Technical
SMA 508.740 (+0.5%)
SMA 2009.822 (-10.6%)
Beta—
S&P 52W Chg19.97%
Avg Vol (30d)74.61K
Avg Vol (10d)12.00K
Technical Indicators
RSI (14)46.5
MACD-0.2065
MACD Signal-0.2126
MACD Hist.+0.0061
BB Upper9.253 SEK
BB Middle8.857 SEK
BB Lower8.460 SEK
BB Width8.94%
ATR (14)0.7672 SEK
Vol Ratio (20d)0.17x